Modern Research Associates

The trials here

What the 8 trials at this site are about, from their registry records.

Conditions

• Atopic dermatitis (eczema)3 trials
• Psoriasis3 trials
• Alopecia areata1 trial
• Hidradenitis suppurativa1 trial

Phase

• Phase 35 trials
• Phase 22 trials
• Phase 2/31 trial

Status

• Completed5 trials
• Active, not recruiting3 trials

Lead sponsor

• Eli Lilly and Company3 trials
• Takeda2 trials
• Amgen1 trial
• Hoffmann-La Roche1 trial
• Janssen Research & Development, LLC1 trial

Running trials

• Active, not recruiting

  A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis

  NCT06863961· Phase 2· Hoffmann-La Roche· Source

• Active, not recruiting

  A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

  NCT06550076· Phase 3· Takeda· Source

• Active, not recruiting

  A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

  NCT06143878· Phase 3· Janssen Research & Development, LLC· Source

Closed trials

• Completed

  A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period

  NCT06108544· Phase 3· Takeda· Source

• Completed

  A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

  NCT06046729· Phase 2· Eli Lilly and Company· Source

• Completed

  A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  NCT05633355· Phase 3· Amgen· Source

• Completed

  Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)

  NCT04392154· Phase 3· Eli Lilly and Company· Source

• Completed

  A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata

  NCT03570749· Phase 2/3· Eli Lilly and Company· Source